Is it safe for a pregnant woman with depression who is already taking citalopram to continue the medication, and what dosing and monitoring are recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 18, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Citalopram Use in Pregnancy

Citalopram can be continued during pregnancy when the benefits of treating maternal depression outweigh the potential risks, as it does not appear to cause major congenital malformations, though neonates exposed late in the third trimester require monitoring for poor neonatal adaptation syndrome. 1, 2

Safety Profile During Pregnancy

Teratogenic Risk

  • Citalopram is not associated with major congenital malformations based on prospective comparative studies showing only 0.9% major malformation rate (1/108 live births), which is not statistically different from unexposed controls 2
  • Animal studies showed teratogenic effects only at maternally toxic doses in rats, with no effects observed in rabbits 1
  • Multiple reviews confirm that citalopram and other older SSRIs appear devoid of teratogenic risks 3, 4

Obstetrical Outcomes

  • Fetal survival rates, mean birth weights, and duration of pregnancy are not statistically different between citalopram-exposed and unexposed pregnancies 2
  • Spontaneous abortion rates (11%) are comparable to disease-matched controls 2

Neonatal Adaptation Syndrome

  • Neonates exposed to citalopram late in the third trimester have a 4.2-fold increased risk (95% CI 1.71-10.26) of admission to special-care nurseries compared to unexposed infants 2
  • Complications requiring prolonged hospitalization may include: respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying 1
  • These features are consistent with either direct toxic effects or drug discontinuation syndrome, and in some cases may represent serotonin syndrome 1

Clinical Decision-Making Algorithm

For Women Already Taking Citalopram

  • Do not abruptly discontinue citalopram when it is required for daily functioning, as untreated maternal depression carries its own risks for both mother and fetus 1
  • Carefully weigh the potential risks of taking an SSRI against the established benefits of treating depression with an antidepressant on a case-by-case basis 1
  • Women who discontinue antidepressants during pregnancy show significant increases in relapse of major depression compared to those who continue treatment 1

Dosing Recommendations

  • Maximum dose is 20 mg/day for patients greater than 60 years of age 1
  • For reproductive-age women without other risk factors, standard dosing of 20-40 mg/day can be used 1
  • Maternal therapeutic drug monitoring should be recommended to minimize fetal exposure, as pregnancy induces CYP2D6 metabolism (54% increase in metabolic ratio), potentially lowering plasma concentrations 5

Monitoring During Pregnancy

Maternal Monitoring

  • Continue standard prenatal care with attention to maternal mental health status 1
  • Monitor for adequate treatment response, as some women may require dose adjustments due to increased drug metabolism during pregnancy 5

Neonatal Monitoring

  • All neonates exposed to citalopram in late third trimester require careful monitoring for signs of poor neonatal adaptation 1, 2
  • Monitor specifically for: respiratory distress, feeding difficulties, temperature instability, jitteriness, irritability, hypoglycemia, and seizures 1
  • Be aware that persistent pulmonary hypertension of the newborn (PPHN) occurs in 1-2 per 1,000 live births generally, with some epidemiologic studies suggesting positive association with SSRI use, though other studies do not show significant association 1

Breastfeeding Considerations

  • Citalopram is excreted in human breast milk at concentrations 2-3 fold higher than maternal plasma concentrations 5
  • However, infant plasma concentrations of citalopram and metabolites are very low or undetectable during breastfeeding 5
  • Two case reports describe infants experiencing excessive somnolence, decreased feeding, and weight loss associated with breastfeeding from citalopram-treated mothers, with recovery upon discontinuation 1
  • The decision to continue or discontinue nursing or citalopram should weigh the risks of infant exposure against the benefits of treatment for the mother 1
  • Neurodevelopment of infants up to 1 year of age has been normal in prospective studies 5

Important Caveats

  • Citalopram and sertraline should be considered first-line SSRI treatments for depression in pregnant women, as they have the most favorable safety profiles compared to paroxetine and fluoxetine which have stronger associations with negative outcomes 4
  • The absolute risk of adverse outcomes remains low even when relative risks are elevated 2
  • Confounding by indication (the underlying depression itself) may contribute to some observed risks 3
  • Untreated depression carries its own substantial risks, including negative impact on emotional development of children and risk of suicide or infanticide in severe cases 3

References

5
Research

Citalopram in pregnancy and lactation.

Clinical pharmacology and therapeutics, 2002

Related Questions

What are the safest antidepressants for a pregnant patient?
Is citalopram (Celexa) safe to use during pregnancy?
Is Citalopram (Celexa) Hydrobromide 40 MG safe during pregnancy?
Can a pregnant patient with a history of depression or anxiety take Effexor (venlafaxine), Wellbutrin (bupropion), or trazodone while pregnant?
What is the best medication option for a pregnant patient with depression at 8 weeks gestation, not currently on any medication, and considering treatment options?
For an adult without contraindications and with mild‑to‑moderate renal impairment, what is the initial dose and titration schedule of Vraylar (cariprazine), and what are its contraindications, renal dosing considerations, common adverse effects, and major CYP3A4 drug interactions?
What dose of hyaluronidase should be injected for a suspected vascular occlusion?
In a perimenopausal woman on daily oral estradiol 0.05 mg plus progesterone 100 mg for hormone replacement therapy who continues to have mild‑to‑moderate anxiety and mild depression affecting quality of life and exercises only 1–2 times per week, what management steps should be taken?
What is the recommended initial evaluation and treatment for a patient with widespread systemic vasculitis?
What changes should be made to the treatment plan for a 64‑year‑old woman with severe obesity, mild tricuspid and mitral regurgitation, type 2 diabetes with hyperglycemia and elevated HbA1c, impaired renal function (eGFR ≈ 48 mL/min/1.73 m²), hypertension on amlodipine and olmesartan‑hydrochlorothiazide, borderline elevated LDL‑C, mildly elevated ALT, currently on NPH insulin (Novolin) and glipizide?
Does progestin‑only contraception increase cervical cancer risk in reproductive‑age women?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question